As of 2025-10-11, the Fair Value of Recursion Pharmaceuticals Inc (RXRX) is -7.48 USD. This value is based on the Peter Lynch's Fair Value formula. With the current market price of 5.32 USD, the upside of Recursion Pharmaceuticals Inc is -240.52%.
With the market price of 5.32 USD and our fair value calculation, Recursion Pharmaceuticals Inc (RXRX) is not a good investment. Investing in RXRX stocks now will result in a potential loss of 240.52%.
Note: valuation result may not be accurate due to the company's negative EPS.
Peter Lynch's formula is:
The earnings growth rate we use in the formula is the average growth rate of net income/earnings over the last 5 years. If the average growth rate is smaller than 5%, we set it to 5%. If it is larger than 25%, we set it to 25%. If the TTM EPS is negative, Peter Lynch Fair Value's result can be unreliable.
| Historical Earnings | ||||||
| 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 5Y Avg | |
| Net income | -87.01 | -186.48 | -239.48 | -328.07 | -463.66 | -260.94 |
| YoY growth | -40.61% | -114.32% | -28.42% | -36.99% | -41.33% | -52.33% |
| Market Cap (mil) | 2,309.68 |
| P/E | |
| Forward P/E |
| EPS | -1.50 |
| Avg earnings growth rate | -52.33% |
| TTM earnings | -649.13 |